132 related articles for article (PubMed ID: 9352573)
21. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.
Schillevoort I; de Boer A; van der Weide J; Steijns LS; Roos RA; Jansen PA; Leufkens HG
Pharmacogenetics; 2002 Apr; 12(3):235-40. PubMed ID: 11927839
[TBL] [Abstract][Full Text] [Related]
22. Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity.
Hedenmalm K; Sundgren M; Granberg K; Spigset O; Dahlqvist R
Ther Drug Monit; 1997 Dec; 19(6):643-9. PubMed ID: 9421105
[TBL] [Abstract][Full Text] [Related]
23. CYP2D6 ultrarapid metabolizer genotype as a potential modifier of smoking behaviour.
Saarikoski ST; Sata F; Husgafvel-Pursiainen K; Rautalahti M; Haukka J; Impivaara O; Järvisalo J; Vainio H; Hirvonen A
Pharmacogenetics; 2000 Feb; 10(1):5-10. PubMed ID: 10739167
[TBL] [Abstract][Full Text] [Related]
24. Complicated pain management in a CYP450 2D6 poor metabolizer.
Foster A; Mobley E; Wang Z
Pain Pract; 2007 Dec; 7(4):352-6. PubMed ID: 17986163
[TBL] [Abstract][Full Text] [Related]
25. Mimicking gene defects to treat drug dependence.
Sellers EM; Tyndale RF
Ann N Y Acad Sci; 2000; 909():233-46. PubMed ID: 10911933
[TBL] [Abstract][Full Text] [Related]
26. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
27. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.
Haufroid V; Hantson P
Clin Toxicol (Phila); 2015 Jul; 53(6):501-10. PubMed ID: 25998998
[TBL] [Abstract][Full Text] [Related]
28. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.
Funck-Brentano C; Boëlle PY; Verstuyft C; Bornert C; Becquemont L; Poirier JM
Eur J Clin Pharmacol; 2005 Dec; 61(11):821-9. PubMed ID: 16315033
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome P450 2D6 polymorphisms and predicted opioid metabolism in African American children with sickle cell disease.
Yee MM; Josephson C; Hill CE; Harrington R; Castillejo MI; Ramjit R; Osunkwo I
J Pediatr Hematol Oncol; 2013 Oct; 35(7):e301-5. PubMed ID: 23619115
[TBL] [Abstract][Full Text] [Related]
30. Hydrocodone in postoperative personalized pain management: pro-drug or drug?
Stauble ME; Moore AW; Langman LJ; Boswell MV; Baumgartner R; McGee S; Metry J; Jortani SA
Clin Chim Acta; 2014 Feb; 429():26-9. PubMed ID: 24269714
[TBL] [Abstract][Full Text] [Related]
31. CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice.
Carranza-Leon D; Dickson AL; Gaedigk A; Stein CM; Chung CP
Pharmacogenomics J; 2021 Aug; 21(4):484-490. PubMed ID: 33750887
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.
Gammal RS; Crews KR; Haidar CE; Hoffman JM; Baker DK; Barker PJ; Estepp JH; Pei D; Broeckel U; Wang W; Weiss MJ; Relling MV; Hankins J
Pediatrics; 2016 Jul; 138(1):. PubMed ID: 27335380
[TBL] [Abstract][Full Text] [Related]
33. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.
Otton SV; Schadel M; Cheung SW; Kaplan HL; Busto UE; Sellers EM
Clin Pharmacol Ther; 1993 Nov; 54(5):463-72. PubMed ID: 7693389
[TBL] [Abstract][Full Text] [Related]
34. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment.
Pérez de los Cobos J; Siñol N; Trujols J; del Río E; Bañuls E; Luquero E; Menoyo A; Queraltó JM; Baiget M; Alvarez E
Drug Alcohol Depend; 2007 Jul; 89(2-3):190-4. PubMed ID: 17234366
[TBL] [Abstract][Full Text] [Related]
35. Chronic Pain Management in a CYP2D6 Poor Metabolizer: A Case Report for Oxycodone.
Pednekar D; Russell J; Bardolia C; Thacker D; Amin NS
Sr Care Pharm; 2024 Apr; 39(4):137-142. PubMed ID: 38528335
[TBL] [Abstract][Full Text] [Related]
36. A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.
Shiran MR; Chowdry J; Rostami-Hodjegan A; Ellis SW; Lennard MS; Iqbal MZ; Lagundoye O; Seivewright N; Tucker GT
Br J Clin Pharmacol; 2003 Aug; 56(2):220-4. PubMed ID: 12895196
[TBL] [Abstract][Full Text] [Related]
37. Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.
Antunes MV; Linden R; Santos TV; Wallemacq P; Haufroid V; Classen JF; Andreolla H; Costa N; Fontanive TO; Rosa DD
Ther Drug Monit; 2012 Aug; 34(4):422-31. PubMed ID: 22777153
[TBL] [Abstract][Full Text] [Related]
38. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.
Eckhardt K; Li S; Ammon S; Schänzle G; Mikus G; Eichelbaum M
Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456
[TBL] [Abstract][Full Text] [Related]
39. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype.
Berecz R; de la Rubia A; Dorado P; Fernández-Salguero P; Dahl ML; LLerena A
Eur J Clin Pharmacol; 2003 May; 59(1):45-50. PubMed ID: 12682803
[TBL] [Abstract][Full Text] [Related]
40. Cytochrome P450 2D6 genotype and methadone steady-state concentrations.
Eap CB; Broly F; Mino A; Hämmig R; Déglon JJ; Uehlinger C; Meili D; Chevalley AF; Bertschy G; Zullino D; Kosel M; Preisig M; Baumann P
J Clin Psychopharmacol; 2001 Apr; 21(2):229-34. PubMed ID: 11270921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
